Viking Therapeutics will present new clinical data on VK2735, its dual GLP-1/GIP agonist for obesity and metabolic disorders, at ObesityWeek 2025 in Atlanta from November 4-7, 20251347.
Two poster presentations are planned:
one with an exploratory analysis of Phase 2 VENTURE trial results and another describing the design of the ongoing Phase 3 VANQUISH-1 trial13.
The VENTURE trial investigated 13 weeks of weekly subcutaneous VK2735 treatment in obese adults, focusing on the drug’s impact on weight, prediabetes prevalence, and cardiometabolic status13.
Preliminary results from VENTURE suggest a reduction in prediabetes and improved metabolic function in high-risk obese populations after VK2735 treatment13.
The VANQUISH-1 study is a large Phase 3 trial aiming to assess the efficacy and safety of subcutaneous VK2735 in overweight or obese adults with at least one weight-related co-morbidity, providing insight into its long-term potential13.
Both subcutaneous and oral formulations of VK2735 are being evaluated by Viking Therapeutics in ongoing and planned clinical trials35.
Sources:
1. https://marketchameleon.com/articles/b/2025/10/30/vktx-highlights-vk2735-clinical-data-obesityweek-aha-2025
3. https://www.moomoo.com/news/post/60515681/viking-therapeutics-to-highlight-clinical-data-from-vk2735-obesity-program
4. https://www.marketscreener.com/news/viking-therapeutics-inc-announces-to-highlight-clinical-data-from-vk2735-obesity-program-in-presen-ce7d5dd3d98df524
5. https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2735/